Core Viewpoint - The article highlights the challenges faced by bank-affiliated insurance companies, particularly focusing on Zhongyin Samsung Life, which has experienced significant losses despite growing premium income, indicating structural issues within the bancassurance model [1][4]. Group 1: Financial Performance - Zhongyin Samsung Life has seen premium income grow from 6.46 million yuan in 2014 to 298.62 million yuan in 2024, marking a 370% increase after the entry of China Bank [2]. - However, net profit has fluctuated significantly, with figures of 0.55 million yuan in 2019 and a peak of 4.83 million yuan in 2024, indicating reliance on short-term investment gains rather than sustainable growth [2]. - In the first half of this year, the company reported insurance business income of 186.45 million yuan, an 8.12% year-on-year increase, but incurred a loss of 5.43 million yuan, the only bank-affiliated insurer to do so [2][5]. Group 2: Liability Reserves - The insurance liability reserves have been increasing, reaching 278.08 million yuan in 2024, with a growth rate of 34.11% from the previous year, indicating rising payout pressures [3]. Group 3: Market Position and Challenges - The bancassurance model, once a strength, has become a constraint as regulatory changes and market competition intensify, leading to a decline in new single premium business for bank-affiliated insurers [4][8]. - Traditional insurers have outperformed bank-affiliated companies in new single premium business, with a 45% growth compared to a 14% decline for the latter [4]. Group 4: Investment Management Issues - Bank-affiliated insurers, including Zhongyin Samsung Life, struggle with independent investment management, leading to lower investment returns, with the company reporting a comprehensive investment yield of 2.39% and total asset investment yield of -0.4% in the first half of this year [6]. Group 5: Shareholder Structure and Future Uncertainty - The sale of a 24% stake by the controlling shareholder, AVIC Group, has not found a buyer, adding uncertainty to the company's future [7]. - The potential exit of AVIC Group could delay a planned capital increase of 2.4 billion yuan, which has already been postponed for three years [8].

市场人士认为，险资频频增持背后，除了银行高股息吸金，背后更蕴含着险企大举加码银保的战略考量。"最近3年，银保期交保费逐步赶上个险，一些头部 公司也将战略重心押注银保，试图通过重仓银行股，借力资本纽带抢占银保市场。"一家中型人身险公司银保业务负责人对智通财经记者表示。 据行业交流数据预测，未来10-15年，银行渠道的新业务价值将是个险的两到三倍，甚至目前仍以个险为主的老七家，其银保新业务价值也将超过个险，老 七家在银保期交的市场份额将从2024年的26%上升至40%左右。 "随着低利率时代到来，利差的收窄对于银行和保险都是大考验，未来二者一定走向抱团取暖，战略联盟、资本纽带绑定双方长期利益将逐渐成为趋势。"一 家头部寿险公司高管对智通财经记者表示。 险资"痴迷"银行股：年内上百次出手增持，10度触发举牌 智通财经7月24日讯（记者 夏淑媛） 险资持续"爆买"银行股。港交所最新权益披露资料显示，近期弘康人寿累计3次增持郑州银行H股。与弘康人寿加仓区 域性城商行不同，平安资产、中国平安则出手增持国有大行邮储H股，二者最新持股比例均超14%。 据智通财经记者统计，开年以来，截至7月22日，平安人寿、新华保险、瑞众人寿 ...